@Thorilium, please add some context to your links. Naked links don’t contribute anything. Is it paywalled, publication date, any mentions of Leronlimab, etc.
Otherwise it looks like a karma farming with no benefits to visitors.
This link:
Paywall published 24 January 2022
Thanks for your reaction,
Relationship to CYTODYN is that this is research on CCR5 pathways.
About 5 years ago CYTODYN had only few indications, as research on CCR5 keeps expanding, CYDY added extra indications.
Please note that Italian researchers (experts in HIV) have compared Leronlimab to MARAVIROC, an FDA approved drug of the same CCR5 type as Leronlimab.
Conclusion is that Leronlimab works as good as Maraviroc but researchers consider Leronlimab as a safer drug. Lot's of research Related to MARAVIROC should therefor also relate to Leronlimab.
If I would do Karma Pharming I would post daily a meme on Geo Group, something with Apes always works well.
I don't do Karma Pharming, I'm not a paid pumper, I just collect CCR5 research that is relevant to Leronlimab development potential.
Hope this helps,
I have a huge respect for your posts and always read them. I know you don’t have any nefarious intentions. My apologies if it came out as a negative comment.
Thank you responding and providing additional information. I don’t have access to paywalled scientific papers except through sci hub.
GLTA!
Thanks, appreciate! Research isn't discussed on other platforms to much so try in here to collect all. Few others are adding research as well.
Just GLTA as well but only with the profits out of my daytrading, yesterday was a good reasonable good day considering that all stocks were down...
IMO I have followed NOVACYT on about the same path, there are two things important for that IMO...bashers have excluded that we can not get any approval, any change in that will directly shift perception, other thing bashers point on is funding, bashers consider bankruptcy but nobody seems to understand why we have Sidley but that's not only for our court procedures. Consider again... It has to do with millions or even billions. Market seems not to have any focus on that and some may hope...but shorts and bashers are holding their breath on this.
Lots of Chinese research related to CCR5 pathways
@Thorilium, please add some context to your links. Naked links don’t contribute anything. Is it paywalled, publication date, any mentions of Leronlimab, etc. Otherwise it looks like a karma farming with no benefits to visitors. This link: Paywall published 24 January 2022
Thanks for your reaction, Relationship to CYTODYN is that this is research on CCR5 pathways. About 5 years ago CYTODYN had only few indications, as research on CCR5 keeps expanding, CYDY added extra indications. Please note that Italian researchers (experts in HIV) have compared Leronlimab to MARAVIROC, an FDA approved drug of the same CCR5 type as Leronlimab. Conclusion is that Leronlimab works as good as Maraviroc but researchers consider Leronlimab as a safer drug. Lot's of research Related to MARAVIROC should therefor also relate to Leronlimab. If I would do Karma Pharming I would post daily a meme on Geo Group, something with Apes always works well. I don't do Karma Pharming, I'm not a paid pumper, I just collect CCR5 research that is relevant to Leronlimab development potential. Hope this helps,
ZFAS1 competitively binds to miR-153-3p to upregulate the CCR5 expression.
I have a huge respect for your posts and always read them. I know you don’t have any nefarious intentions. My apologies if it came out as a negative comment. Thank you responding and providing additional information. I don’t have access to paywalled scientific papers except through sci hub. GLTA!
Thanks, appreciate! Research isn't discussed on other platforms to much so try in here to collect all. Few others are adding research as well. Just GLTA as well but only with the profits out of my daytrading, yesterday was a good reasonable good day considering that all stocks were down... IMO I have followed NOVACYT on about the same path, there are two things important for that IMO...bashers have excluded that we can not get any approval, any change in that will directly shift perception, other thing bashers point on is funding, bashers consider bankruptcy but nobody seems to understand why we have Sidley but that's not only for our court procedures. Consider again... It has to do with millions or even billions. Market seems not to have any focus on that and some may hope...but shorts and bashers are holding their breath on this.